A Study for Treatment of Paroxysmal Atrial Fibrillation (PAF) by Pulsed Field Ablation (PFA) System With Irreversible Electroporation (IRE)
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 272 participants.
Also called NCT04524364
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 272 participants
- Sponsor
- Registry
-
NCT04524364
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Austria, Belgium, Canada, Croatia, Czechia, France, Italy, Lithuania
- Registry status
- Completed
Technical summary
Registry record NCT04524364. Allocation not applicable; no masking; primary purpose treatment. Start 2020-08-23 (actual); primary completion 2023-05-09 (actual). Results posted on 2024-05-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study for Treatment of Paroxysmal Atrial Fibrillation (PAF) by Pulsed Field Ablation (PFA) System With Irreversible Electroporation (IRE)
- Acronym
- inspIRE
- Condition
- Atrial Fibrillation
- Intervention (Device)
- Pulsed Field Ablation (PFA) Therapy
- Lead sponsor
- Biosense Webster, Inc.
Record details
- Record id
cardio:ct-nct04524364- Content hash
21e1e470a617a152c58cafa10d628e971c46185c6375ad0530442e2c7d66505f